Lynch Norge patient association officially registered: A new voice for people with Lynch syndrome

Many people in Norway with Lynch syndrome—a hereditary condition that carries a high risk of developing cancer—have long felt the need for an organization of their own to represent them. Lynch Norge has now been established to address this need. This is a direct result of PREDI-LYNCH, a research and innovation project aiming to determine whether blood tests, combined with risk models based on artificial intelligence, can help prevent cancer in individuals with Lynch syndrome. PREDI-LYNCH is funded through the EU’s Cancer Mission under the Horizon Europe programme, involving 16 different countries, including Norway.

Mev Dominguez-Valentin is the coordinator of PREDI-LYNCH and leads the Inherited and Familial Cancer research group at the Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital.  

Translated from news article at Cancer Mission Hub Norway:

The exact number of people in Norway with Lynch syndrome is not known. However, studies from other countries estimate that approximately one in 470 people has this condition. In Norway, this corresponds to around 12,000 individuals, explains Dominguez-Valentin.

“These individuals are at a very high risk of developing cancer, and the same applies to their children. I hope that the new organization will help raise awareness of their needs and the need for further research in this area, so that people with Lynch syndrome can lead better lives,” she says.

"It is a milestone that individuals with Lynch syndrome now have their own patient organization to represent them and their needs," says Sigbjørn Smeland, Head of the Division of Cancer Medicine at Oslo University Hospital. 

"We congratulate Lynch Norge on its establishment. It is challenging to be born with a genetic defect that puts both you—and potentially several other family members—at high risk of developing cancer. It is important that people living with Lynch syndrome are seen and heard, and I believe that Lynch Norge will contribute to this," says Smeland.

"I also have faith that research—not least through the PREDI-LYNCH project—will provide us with new and important knowledge, and in doing so, improve life for people with Lynch syndrome," he adds.


Original news article from the homepage of Cancer Mission Hub Norway (in Norwegian):
En ny stemme for personer med Lynch syndrom (cancermission.no)


About PREDI-LYNCH:

"Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome, PREDI-LYNCH"  
was officially launched on May 1st, 2025 and is funded by the European Commission Horizon Europe Mission on Cancer with 13.6 million Euro.

  • PREDI-LYNCH will run for six years (2025-2031)
  • The consortium consists of 29 partners from 16 European countries.
  • The initiative is led by researcher Mev Dominguez Valentin at the Institute for Cancer Research, Oslo University Hospital (OUH).
  • In addition, the University of Oslo (UiO) and Oslo Cancer Cluster (OCC) are partners in this ambitious research and innovation project

PREDI-LYNCH homepage (predi-lynch.eu)